GENITOURINARY CANCERS

Patients with urothelial cancer whose tumors overexpress c-Met may benefit from this unique combination.

Fluorodeoxyglucose PET/CT and sodium fluoride PET/CT and percent change in lesion number may be associated with overall survival in patients with metastatic genitourinary malignancies.

An exploratory analysis of the phase 3 JAVELIN Bladder 100 trial shows that the overall survival benefit of frontline maintenance avelumab is sustained in patients with advanced urothelial cancer.

Results from the combination of lenvatinib and pembrolizumab show similarity with the comparator in the phase 3 LEAP-011 study.

Based on pooled long-term data, the safety of darolutamide is solidified in patients with metastatic castration resistant prostate cancer.

Utilizing 18F-rhPSMA-7.3 imaging, detection rates for prostate cancer recurrence were favorable in the phase 3 SPOTLIGHT study.

In a subgroup analysis of the ARAMIS study, the safety and efficacy of darolutamide were not impacted by patients having comorbidities and receiving concomitant medications.

According to results from the phase 3b PRESIDE trial, use of continuous enzalutamide may extend progression-free survival in men with chemotherapy-naïve metastatic castration-resistant prostate cancer.

Results from the ARASENS trials demonstrate superior survival outcomes with darolutamide versus placebo plus androgen deprivation therapy and docetaxel.

In an interview with Targeted Oncology™, Clayton Lau, MD, discussed the impact of COVID-19 on managing genitourinary cancers.

Scott T. Tagawa, MD, FACP, shares clinical pearls and advice for the management of mCRPC.

An expert in prostate cancer comments on emerging agents and combinations in the pipeline for the treatment of mCRPC.

Scott T. Tagawa, MD, FACP, shares his thoughts on remaining questions for imaging and PSMA-targeted therapy for mCRPC.

Dr Scott T. Tagawa discusses common adverse events associated with 177Lu-PSMA-617 in patients with mCRPC and how to appropriately manage them.

A prostate cancer expert considers clinical implications from the phase 3 VISION study, including the potential role of 177Lu-PSMA-617 therapy for patients with mCRPC.

Scott T. Tagawa, MD, FACP, reviews the phase 3 VISION trial evaluating the use of 177Lu-PSMA-617 therapy in patients with mCRPC.

An expert in prostate cancer reviews available options for the treatment of mCRPC and considerations for selecting the optimal therapy.

Dr Scott T. Tagawa reviews traditional imaging techniques and advances in imaging used in clinical practice for prostate cancer.

Scott T. Tagawa, MD, FACP, discusses the heterogeneity and features of prostate cancer and provides insight on biomarker testing.

Tomasz M. Beer, MD, FACP, shares unmet needs and clinical pearls for the management of patients with mCRPC.

An expert in prostate cancer comments on selecting the optimal systemic therapy for metastatic castration-resistant prostate cancer (mCRPC) treatment.

Tomasz M. Beer, MD, FACP, shares his personal experience using darolutamide for patients with CRPC and discusses his approach to patient selection of the drug in the metastatic setting.

Dr Tomasz M. Beer reviews the use of darolutamide for nonmetastatic CRPC as seen in the ARAMIS trial and metastatic CRPC as seen in the ODENZA trial.

Prostate cancer expert Tomasz M. Beer, MD, FACP, provides insight on the use of molecular and biomarker testing for a patient with mCRPC.

Dr Tomasz M. Beer comments on approaching first-line therapy for a patient with metastatic castration-resistant prostate cancer (mCRPC).